{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:24:38Z","timestamp":1787027078037,"version":"build-2736575974"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Macrophage activation syndrome (MAS) is a life-threatening condition characterized by the excessive stimulation of macrophages and T lymphocytes, provoked by infections, malignancy, and autoimmune or autoinflammatory conditions such as systemic juvenile idiopathic arthritis (sJIA). Clinical signs of sJIA may include high-spiking, quotidian fevers, lymphadenopathy, hepatosplenomegaly, and a salmon-colored migratory, evanescent rash. By contrast, MAS is characterized by unremitting fevers and diffuse, fixed, maculopapular rashes. In addition to hepatosplenomegaly and lymphadenopathy, patients with MAS may also have clinical signs of coagulopathy, as well as cardiac, lung, renal, and central nervous system dysfunction. The empiric treatment for MAS is initially high-dose IV corticosteroids, but usually requires addition of immunomodulators such as tacrolimus or a biologic such as Anakinra to control. The addition of immunotherapies for MAS has improved patient outcomes. We present a 2-year-old male patient with a history of early-onset sJIA, who presented with MAS refractory to corticosteroids and anakinra triggered by adenoviremia that required addition of emapalumab to control. We believe this is the first reported case of a combination of immunosuppressive therapy of emapalumab, etoposide, anakinra, tacrolimus, and corticosteroids used in the successful treatment of infection-induced MAS in early-onset sJIA. Given the lack of treatment guidelines and approved therapies for MAS, alternative strategies should be considered for patients with an intractable course.<\/jats:p>","DOI":"10.3389\/fped.2023.1336554","type":"journal-article","created":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T23:21:55Z","timestamp":1705879315000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Case Report: Refractory macrophage activation syndrome requiring high-dose anakinra, emapalumab, and etoposide therapy in early-onset systemic juvenile idiopathic arthritis associated with adenoviremia"],"prefix":"10.3389","volume":"11","author":[{"given":"Elizabeth D.","family":"Slaney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee","family":"Modica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandra","family":"Woolnough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Kafisheh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise Heather","family":"Bell-Brunson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Elder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3389\/fimmu.2019.00119","article-title":"The immunology of macrophage activation syndrome","volume":"10","author":"Crayne","year":"2019","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.hoc.2015.06.010","article-title":"Macrophage activation syndrome","volume":"29","author":"Ravelli","year":"2015","journal-title":"Hematol Oncol Clin North Am"},{"key":"B3","doi-asserted-by":"publisher","first-page":"7213939","DOI":"10.1155\/2021\/7213939","article-title":"Familial hemophagocytic lymphohistiocytosis secondary to PRF1 mutation","volume":"2021","author":"Alfaraidi","year":"2021","journal-title":"Case Rep Hematol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s12288-014-0494-x","article-title":"Familial hemophagocytic lymphohistiocytosis due to mutation of UNC13D gene","volume":"32","author":"Giri","year":"2016","journal-title":"Indian J Hematol Blood Transfus"},{"key":"B5","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12881-018-0600-2","article-title":"Identification of a novel nonsense mutation in the UNC13D gene from a patient with hemophagocytic lymphohistiocytosis: a case report","volume":"19","author":"Hu","year":"2018","journal-title":"BMC Med Genet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1111\/ijlh.13674","article-title":"Spectrum mutations of PRF1, UNC13D, STX11, and STXBP2 genes in Vietnamese patients with hemophagocytic lymphohistiocytosis","volume":"43","author":"Xinh","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/humu.20274","article-title":"Mutation spectrum in children with primary hemophagocytic lymphohistiocytosis: molecular and functional analyses of PRF1, UNC13D, STX11, and RAB27A","volume":"27","author":"Zur Stadt","year":"2006","journal-title":"Hum Mutat"},{"key":"B8","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/j.1442-200X.2012.03683.x","article-title":"SAP and XIAP deficiency in hemophagocytic lymphohistiocytosis","volume":"54","author":"Yang","year":"2012","journal-title":"Pediatr Int"},{"key":"B9","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/art.39332","article-title":"2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European league against rheumatism\/American College of Rheumatology\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative","volume":"68","author":"Ravelli","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/art.41103","article-title":"Benefit of anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis","volume":"72","author":"Eloseily","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1007\/s10067-018-4095-1","article-title":"Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature","volume":"37","author":"S\u00f6nmez","year":"2018","journal-title":"Clin Rheumatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e358","DOI":"10.1016\/S2665-9913(20)30096-5","article-title":"Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome","volume":"2","author":"Mehta","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"635080","DOI":"10.3389\/fped.2020.635080","article-title":"Case report: life-threatening macrophage activation syndrome with fulminant myocarditis successfully rescued by high dose intravenous anakinra","volume":"8","author":"Meneghel","year":"2021","journal-title":"Front Pediatr"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e28581","DOI":"10.1002\/pbc.28581","article-title":"The use of anakinra in the treatment of secondary hemophagocytic lymphohistiocytosis","volume":"67","author":"Bami","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","article-title":"Emapalumab in children with primary hemophagocytic lymphohistiocytosis","volume":"382","author":"Locatelli","year":"2020","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1080\/17512433.2021.1901576","article-title":"Emapalumab for adult and pediatric patients with hemophagocytic lymphohistiocytosis","volume":"14","author":"Garonzi","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1136\/ard-2022-223739","article-title":"Efficacy and safety of emapalumab in macrophage activation syndrome","volume":"82","author":"De Benedetti","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"O84","DOI":"10.1186\/1546-0096-13-S1-O84","article-title":"High levels of interferon-gamma (IFNg) in macrophage activation syndrome (MAS) and CXCL9 levels as a biomarker for IFNg production in MAS","volume":"13","author":"Bracaglia","year":"2015","journal-title":"Pediatric Rheumatology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1136\/annrheumdis-2020-eular.3169","article-title":"OP0290 emapalumab (anti-interferon-gamma monoclonal antibody) in patients with macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (SJIA)","volume":"79","author":"De Benedetti","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1123104","DOI":"10.3389\/fped.2023.1123104","article-title":"Case report: Emapalumab for active disease control prior to hematopoietic stem cell transplantation in refractory systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome","volume":"11","author":"Chellapandian","year":"2023","journal-title":"Front Pediatr"},{"key":"B22","doi-asserted-by":"publisher","first-page":"887","DOI":"10.21037\/atm-20-3127","article-title":"Successful treatment of secondary macrophage activation syndrome with emapalumab in a patient with newly diagnosed adult-onset still\u2019s disease: case report and review of the literature","volume":"8","author":"Gabr","year":"2020","journal-title":"Ann Transl Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.3899\/jrheum.200941","article-title":"Efficacy of moderately dosed etoposide in macrophage activation syndrome-hemophagocytic lymphohistiocytosis","volume":"48","author":"Horne","year":"2021","journal-title":"J Rheumatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/jca.21570","article-title":"Role of plasma exchange, leukocytapheresis, and plasma diafiltration in management of refractory macrophage activation syndrome","volume":"33","author":"Kinjo","year":"2018","journal-title":"J Clin Apher"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1007\/s00431-013-2093-5","article-title":"Successful remission induced by plasma exchange combined with leukocytapheresis against refractory systemic juvenile idiopathic arthritis","volume":"173","author":"Miyazono","year":"2014","journal-title":"Eur J Pediatr"},{"key":"B26","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1136\/annrheumdis-2019-216699","article-title":"Tofacitinib in refractory adult-onset still\u2019s disease: 14 cases from a single centre in China","volume":"79","author":"Hu","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1093\/mr\/roab119","article-title":"Effective therapy of tocilizumab on systemic juvenile idiopathic arthritis-associated refractory macrophage activation syndrome","volume":"32","author":"Wu","year":"2022","journal-title":"Mod Rheumatol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.revmed.2015.10.348","article-title":"Syndrome d'activation macrophagique sous tocilizumab: mythe ou r\u00e9alit\u00e9? [Macrophage activation syndrome secondary to tocilizumab: myth or reality?]","volume":"37","author":"Deroux","year":"2016","journal-title":"Rev Med Interne"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1336554\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T23:21:58Z","timestamp":1705879318000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1336554\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,22]]},"references-count":28,"alternative-id":["10.3389\/fped.2023.1336554"],"URL":"https:\/\/doi.org\/10.3389\/fped.2023.1336554","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,22]]},"article-number":"1336554"}}